Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 and Toripalimab with Chemotherapy in Neoadjuvant TNBC
NCT07101614Phase 2Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Sep 2025
- Primary completion
- Nov 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of tifcemalimab in triple-negative breast cancer (TNBC), sponsored by Shengjing Hospital of China Medical University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tifcemalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07101614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101614.